Human umbilical cord mesenchymal stem cell transplantation on diabetic peripheral neuropathy

Study of effect of human umbilical cord mesenchymal stem cell transplantation on diabetic peripheral neuropathy

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIN-17010524

Enrollment

Unknown

Registered

2017-01-26

Start date

2017-01-05

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Interventions

case:hereditary cerebellar ataxia

control:conventional therapy

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Have a clear history of diabetes; 2. sensory dysfunction, knee, Achilles tendon reflexes weaken or disappear TCSS=6 neurophysiological abnormalities; 3. No other neuropathic drugs can be administered within six months after enrollment and during follow-up.

Exclusion criteria

Exclusion criteria: 1. Nearly 3 months of application of other drugs in patients with neuropathy; 2. Severe leg ulcers or gangrene, not suitable for line lower limb intervention; 3. cancer; 4. Severe heart, liver and kidney disease; 5. Suffering from peripheral neuropathy can lead to other diseases; 6. Infection not fully controlled.

Design outcomes

Primary

Measure	Time frame
blood sugar;HbA1C levels;Toronto clinical scoring system;electrophysiological examination;	—

Countries

China

Contacts

Public ContactAn yihua

General Hospital of Chinese People's Armed Police Forces

riveran@126.com+86 010-57976848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026